{
    "ticker": "TCBP",
    "name": "TC Biopharm plc",
    "description": "TC Biopharm plc is a clinical-stage biotechnology company focused on the development of innovative immune cell therapies for the treatment of cancer and infectious diseases. Founded in 2014, the company is headquartered in Glasgow, Scotland, and aims to revolutionize cancer treatment with its proprietary platform, which harnesses the power of the body's immune system. TC Biopharm's lead product candidate, TC-110, is an allogeneic, off-the-shelf immunotherapy designed to target and eliminate cancer cells. The company is committed to advancing its therapies through rigorous clinical trials aimed at demonstrating safety and efficacy. With a passionate team of scientists and medical professionals, TC Biopharm is dedicated to improving patient outcomes and enhancing quality of life for individuals battling cancer. The company focuses on leveraging advanced technology and scientific expertise to develop treatments that can potentially address significant unmet medical needs in oncology and beyond. As it progresses through clinical trials, TC Biopharm aims to bring its promising therapies to market and expand its portfolio of innovative solutions that harness the immune system.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Glasgow, Scotland, UK",
    "founded": "2014",
    "website": "https://www.tcbiopharm.com",
    "ceo": "Bobby L. D. B. P. C. A. C. E. W. McCulloch",
    "social_media": {
        "twitter": "https://twitter.com/TCBiopharm",
        "linkedin": "https://www.linkedin.com/company/tc-biopharm-plc/"
    },
    "investor_relations": "https://www.tcbiopharm.com/investors",
    "key_executives": [
        {
            "name": "Bobby L. D. B. P. C. A. C. E. W. McCulloch",
            "position": "CEO"
        },
        {
            "name": "Dr. Samir P. N. M. B. K. M. G. F. W. O. H. K. P. K. P. D. K. A. A. M. K. B. K. K. L. A. I. M. C.",
            "position": "Chief Scientific Officer"
        }
    ],
    "product_categories": [
        {
            "category": "Immunotherapy",
            "products": [
                "TC-110"
            ]
        }
    ],
    "seo": {
        "meta_title": "TC Biopharm plc | Innovative Immune Cell Therapies",
        "meta_description": "Explore TC Biopharm plc, a clinical-stage biotechnology company dedicated to developing immune cell therapies for cancer treatment. Learn about our innovative approaches and product pipeline.",
        "keywords": [
            "TC Biopharm",
            "Immunotherapy",
            "Cancer Treatment",
            "Biotechnology",
            "Clinical Trials"
        ]
    },
    "faq": [
        {
            "question": "What does TC Biopharm specialize in?",
            "answer": "TC Biopharm specializes in developing immune cell therapies for cancer and infectious diseases."
        },
        {
            "question": "Where is TC Biopharm headquartered?",
            "answer": "TC Biopharm is headquartered in Glasgow, Scotland, UK."
        },
        {
            "question": "What is TC Biopharm's lead product candidate?",
            "answer": "TC Biopharm's lead product candidate is TC-110, an allogeneic immunotherapy."
        },
        {
            "question": "When was TC Biopharm founded?",
            "answer": "TC Biopharm was founded in 2014."
        }
    ],
    "competitors": [
        "CRSP",
        "KITE",
        "ZIOP"
    ],
    "related_stocks": [
        "GILD",
        "AMGN",
        "BMY",
        "JNJ"
    ]
}